Daniel C. Javitt Sells 784,063 Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPGet Rating) major shareholder Daniel C. Javitt sold 784,063 shares of the firm’s stock in a transaction on Friday, July 29th. The stock was sold at an average price of $1.01, for a total value of $791,903.63. Following the transaction, the insider now owns 9,872,901 shares in the company, valued at $9,971,630.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $0.82 on Thursday. The business’s fifty day moving average price is $0.60 and its 200 day moving average price is $1.84. NRx Pharmaceuticals, Inc. has a 12-month low of $0.49 and a 12-month high of $19.75. The stock has a market capitalization of $54.31 million, a PE ratio of -0.09 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.83 and a quick ratio of 3.83.

NRx Pharmaceuticals (NASDAQ:NRXPGet Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.25) earnings per share (EPS) for the quarter. Equities research analysts forecast that NRx Pharmaceuticals, Inc. will post -0.43 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright started coverage on NRx Pharmaceuticals in a research note on Thursday, June 30th. They set a “buy” rating and a $2.00 price objective on the stock.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Ursa Fund Management LLC bought a new stake in NRx Pharmaceuticals in the first quarter valued at $37,000. State Street Corp lifted its stake in NRx Pharmaceuticals by 1,009.1% in the first quarter. State Street Corp now owns 114,240 shares of the company’s stock valued at $280,000 after buying an additional 103,940 shares during the last quarter. Renaissance Technologies LLC bought a new stake in NRx Pharmaceuticals in the first quarter valued at $341,000. Northern Trust Corp lifted its stake in NRx Pharmaceuticals by 61.5% in the first quarter. Northern Trust Corp now owns 58,598 shares of the company’s stock valued at $144,000 after buying an additional 22,322 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in NRx Pharmaceuticals by 1.9% in the first quarter. BlackRock Inc. now owns 525,493 shares of the company’s stock valued at $1,287,000 after buying an additional 10,045 shares during the last quarter. 3.87% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

(Get Rating)

NRX Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.